SHL Group is looking forward to exhibiting at the 2019 Pharmapack, Europe's dedicated pharmaceutical packaging and drug delivery event from February 6-7 in Paris, France.
At the center of this year's exhibition is Molly® 2.25, SHL's high volume variation of its classic Molly® auto injector, designed with a preconfigured technology to help pharmaceutical companies minimize initial equipment investments and speed up development timelines. Boasting an intuitive design that meets a variety of patient handling profiles, Molly® 2.25 supports the trend for injection volumes in the 1-2.25mL range to meet the increasing need for the simple delivery of larger doses. SHL is also looking forward the market introduction of the first drug product based on the Molly® 2.25 program.
Another highlight at this year's event is the range of auto injectors built with SHL's Needle Isolation Technology (NIT®). This proprietary technology allows cartridge-based injection devices to be built as easy-to-use auto injectors with permanently hidden needles. “The NIT® is a true problem solver because cartridges not only open up a world of opportunities for pharma companies, it also offers patients a safe and intuitive experience without sacrificing usability,” said Magnus Fastmarken, SHL's global director of marketing.
This year, SHL is again pairing up with Innovation Zed to present InsulCheck at Pharmapack's Innovation Gallery. This year's display, InsulCheck Connect, is a smart pen injector add-on that displays the time elapsed since last injection. It can be connected to 3rd party service applications to track insulin injection. InsulCheck Connect is compatible with a *variety of existing insulin injection pens on the market and can be customized to support other pen injector projects.
Visitors are invited to explore SHL's innovative injectable drug delivery solutions at Stand B44 at the Paris Expo Porte de Versailles.
SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.
With over 4,000 employees worldwide, SHL Group consists of several distinct group companies:
SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.
SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information, visit www.shl.group.